儿童体外循环心脏术后止血血液制品的使用及相关结局
这项回顾性队列研究纳入2011至2017年单中心PICU中0-18岁体外循环心脏手术患儿420例,中位年龄0.8岁,58%为男性,多数为RACHS-2(54%)或RACHS-3(30%)。24%(102/420)术后接受至少一种止血输血,首个产品最常见为血小板(47/102),其次血浆(44/102)和冷沉淀(11/102)。接受止血输血者年龄更小、体重更低、更少为首次体外循环手术、手术更复杂、体外循环时间更长、更多使用深低温停循环。术后接受止血血制品与机械通气天数更多(p<0.001)和PICU住院时间更长(p=0.001)独立相关,但与血管活性药物使用时间(p=0.113)或院内感染(p=0.299)无关。作者结论认为这些血制品与更差临床结局独立相关,需更大规模研究确定其止血疗效及相关并发症以指导合理血液管理。
要点
- 420例体外循环心脏手术患儿中24%(102/420)术后接受至少一种止血输血,首个产品最常见为血小板(47/102),其次血浆(44/102)和冷沉淀(11/102)。
- 接受止血输血者年龄更小(p=0.006)、体重更低(p=0.004)、更少为首次体外循环手术(p=0.003)、手术更复杂(p=0.001)、体外循环时间更长(p<0.001)、更多使用深低温停循环(p=0.014)。
- 术后接受止血血制品与机械通气天数更多(p<0.001)和PICU住院时间更长(p=0.001)独立相关。
- 术后接受止血血制品与血管活性药物使用时间(p=0.113)或院内感染(p=0.299)无独立关联。
- 作者认为需更大规模研究确定这些血制品的止血疗效及相关并发症,以指导合理血液管理。
适用人群与场景
- 2011至2017年单中心三级医疗中心PICU中0-18岁接受体外循环心脏手术的儿童,共420例。
- 中位年龄0.8岁(四分位距0.3-5岁),243例(58%)为男性。
- 多数病例为RACHS-2(223例,54%)或RACHS-3(124例,30%)。
研究设计与关键结果
- 研究类型为回顾性队列研究,单中心三级医疗中心PICU,2011至2017年,纳入420例0-18岁体外循环心脏手术患儿,无干预。
- 24%(102/420)患儿接受至少一种止血输血,首个产品最常见为血小板(47/102),其次血浆(44/102)和冷沉淀(11/102)。
- 接受止血输血者与未接受者相比:年龄更小(p=0.006)、体重更低(p=0.004)、更少为首次体外循环手术(p=0.003)、手术更复杂(p=0.001)、体外循环时间更长(p<0.001)、更多使用深低温停循环(p=0.014)。
- 术后接受止血血制品与机械通气天数更多(p<0.001)和PICU住院时间更长(p=0.001)独立相关。
- 术后接受止血血制品与血管活性药物使用时间(p=0.113)或院内感染(p=0.299)无独立关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需更大规模研究确定这些血制品的止血疗效及相关并发症,以指导合理血液管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To describe the use of hemostatic transfusions in children following cardiac surgery with cardiopulmonary bypass and the association of hemostatic transfusions postoperatively with clinical outcomes.
DESIGN: A retrospective cohort study.
SETTING: PICU of a tertiary care center from 2011 to 2017.
PATIENTS: Children 0-18 years old undergoing cardiac surgery with cardiopulmonary bypass.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Four-hundred twenty children underwent cardiac surgery with cardiopulmonary bypass. The median (interquartile range) age was 0.8 years (0.3-5 yr) and 243 (58%) were male. The majority of cases were classified as Risk Adjustment for Congenital Heart Surgery 2 (223, 54%) or Risk Adjustment for Congenital Heart Surgery 3 (124, 30%). Twenty-four percent of children (102/420) received at least one hemostatic transfusion with the most common first product being platelet transfusions (47/102), followed by plasma (44/102), and cryoprecipitate (11/102). The children who received hemostatic transfusions were younger (p = 0.006), had lower body weights (p = 0.004), less likely to be their initial operation with cardiopulmonary bypass (p = 0.003), underwent more complex surgeries (p = 0.001) with longer bypass runs (p < 0.001), and had more use of hypothermic circulatory arrest (p = 0.014). The receipt of hemostatic blood products postoperatively was independently associated with more days of mechanical ventilation (p < 0.001) and longer PICU lengths of stay (p = 0.001) but not with time receiving vasoactive mediations (p = 0.113) or nosocomial infections (p = 0.299).
CONCLUSIONS: Nearly one-quarter of children undergoing cardiac repair with cardiopulmonary bypass receive hemostatic transfusions postoperatively. These blood products are independently associated with worse clinical outcomes. Larger studies should be performed to determine the hemostatic efficacy of these products, as well as to clarify associated morbidities, in order to inform proper blood management.
参考来源
- Closson R, Mauer E, Stock A, et al. The Use of Hemostatic Blood Products in Children Following Cardiopulmonary Bypass and Associated Outcomes. Crit Care Explor. 2020. PMID: 32832911. doi:10.1097/CCE.0000000000000172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。